However, more severe damage of heart tissue was founded in A20 knock down mice mediated by LV-shA20 compared with LV-ctrl group mice received 40 mg/kg AST-IV treatment, evidenced by more increasing inflammation and necrosis lesions (myocarditis score 3.25 ± 0.25 versus 1.35 ± 0.15, P < 0.05; Fig.6D), indicating that A20 knock down could abrogate the therapeutic effect of AST-IV. Here, TNFAIP3 is linked to myocarditis.